Gottfried E Konecny, MD

Cote ML et al. The growing burden of endometrial cancer: A major racial disparity affecting black women. Cancer Epidemiol Biomarkers Prev 2015;24(9):1407-15. Abstract

Konstantinopoulos PA et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol 2019;37(30):2786-94. Abstract

Makker V et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 2020;38(26):2981-92. Abstract

Marabelle A et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38(1):1-10. Abstract

Oaknin A et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET. ESMO 2020;Abstract LBA36.

J Mansoor Raza Mirza, MD

A multicenter, open-label, randomized, phase 3 trial to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in participants with advanced endometrial cancer. NCT03517449

Cancer Genome Atlas Research Network et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73. Abstract

Leon-Castillo A et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38(29):3388-97. Abstract

Talhouk A et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113(2):299-310. Abstract

Westin SN et al. DUO-E/GOG-3041/ENGOT-EN10: A randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC). ASCO 2020;Abstract TPS6108.

Brian M Slomovitz, MD, MS

Aghajanian C et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2011;29(16):2259-65. Abstract

Alexandrov LB et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463):415-21. Abstract

An umbrella study of INCMGA00012 alone and in combination with other therapies in participants with advanced or metastatic endometrial cancer who have progressed on or after platinum-based chemotherapy (POD1UM-204). NCT04463771

Makker V et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):711-8. Abstract

Ott PA et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. J Clin Oncol 2017;35(22):2535-41. Abstract

Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012;18(21):5856-64. Abstract